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Abstract Drug malabsorption is a potential concern after
bariatric surgery. We present four case reports of hypothy-
roid patients who were well replaced with thyroxine tablets
to euthyroid thyrotropin (TSH) levels prior to Roux-en-Y
gastric bypass surgery. These patients developed elevated
TSH levels after the surgery, the TSH responded reversibly
to switching from treatment with oral tablets to a liquid
formulation.
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Introduction
Global demand for bariatric surgery has increased dramati-
cally in the past decade [1]. This procedure refers to various
surgical techniques employed for achieving weight loss.
Drug malabsorption is a potential postsurgical concern,
particularly after diversionary procedures, for many reasons.
Nearly all oral agents are maximally absorbed in the small
intestine, which is bypassed in several bariatric procedures.
Delayed gastric emptying, diminished opportunity for mucosal
exposure, and changes in drug dissolution and solubility
resulting from alterations in intestinal pH are additional factors
that may potentially impair drug absorption [2, 3].
Levothyroxine (L-T4) is an effective replacement therapy
for patients with hypothyroidism or suppressive therapy after
surgical removal of thyroid cancer [4, 5]. Absorption of L-T4
is reduced when it is ingested concomitantly with other drugs
or with coffee [6] and also when gastric pH is altered by
autoimmune gastritis or by infection with Helicobacter py-
lori [7, 8]. Evidence for diminished L-T4 absorption has been
reported in patients after bariatric surgery [3, 9, 10].
We observed an increase in serum thyrotropin (TSH)
levels after bariatric surgery in a previously euthyroid patient
receiving L-T4 in tablet form. This condition was reversibly
resolved by switching to the same dose in a liquid oral
formulation. We subsequently identified three additional sta-
ble hypothyroid patients submitted to bariatric surgery, who
normalised serum TSH after switching from tablets to the
oral liquid formulation.
Patients and Methods
Serum concentrations of free thyroxine (fT4; normal range,
8.0–19.0 pg/mL; analytical sensitivity, 1 pg/mL; intra and
inter-assay coefficient of variation, 2.4 and 6.8%, respectively),
free triiodothyronine (fT3; normal range, 2.4–4.7; analytical
sensitivity, 0.35 pg/mL; intra and inter-assay coefficient of
variation, 4.6 and 6.5 %, respectively), and TSH (normal range,
0.4–4.5 mIU/L; analytical sensitivity, 0.004 mlU/L; intra and
inter-assay coefficient of variation, 2.5 and 5.7 %, respectively)
were measured by means of immunochemoluminiscent assays
using an automated analyser (Immulite 2000, DPC Cirrus, Los
Angeles, CA, USA) employing commercial kits (Diagnostic
Products Corporation, Los Angeles, CA, USA).
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Case Reports
Patient 1 was a 64-year-old obese Caucasian woman (BMI,
44.6 kg/m2) who was receiving stable substitutive therapy
for hypothyroidism due to Hashimoto’s thyroiditis. In No-
vember 2009, she underwent bariatric surgery (Roux-en-Y
gastric bypass). She was euthyroid receiving 200 μg L-T4
daily in tablet form. One year after surgery, she had lost
35 kg, but her thyroid hormone profile revealed subclinical
hypothyroidism. We changed the formulation from oral tab-
lets to liquid, maintaining the same dosage. After 2 months,
her TSH levels were in the normal range and she felt better.
To confirm the presumed relationship between oral formula-
tion and TSH normalisation, L-T4 was re-administered at the
same dosage in tablet form. Once again, serum TSH increased
(Table 1). The patient verified medication compliance.
Patient 2 was a 33-year-old obese Caucasian woman
(BMI, 45.8 kg/m2) who was receiving stable replacement
therapy after a thyroidectomy for benign multinodular goitre.
In September 2010, she underwent Roux-en-Y gastric by-
pass. She had been euthyroid receiving 150 μg daily of L-T4
tablets. One year after surgery, she had lost 41 kg. At that
time, her serum TSH was 12.1 mIU/L, fT4 was 10.2 pg/mL,
and fT3 was 3.2 pg/mL. Based on our previous experience
with patient 1, we decided to switch from tablets to an oral
liquid formulation, maintaining the same dosage also in this
case. Euthyroidism was restored after 2 months. Once again,
when L-T4 was re-administered in tablet form at the same
dosage, serum TSH levels increased (Table 1).
Patient 3 was a 29-year-old obese Caucasian woman
(BMI, 45.1 kg/m2) who was receiving stable replacement
therapy for Hashimoto’s thyroiditis. In December 2010, she
underwent Roux-en-Y gastric bypass surgery. She was eu-
thyroid receiving 200 μg of L-T4 daily in tablet form. One
year after surgery, she had lost 39 kg; however, her thyroid
profile had worsened. Also in this case, we introduced an
oral liquid formulation, maintaining the same dosage, and
obtained a rapid normalisation of TSH levels. Once again,
when L-T4 was re-administered in tablet form at the same
dosage, serum TSH increased (Table 1).
Patient 4 was a 39-year-old obese Caucasian woman
(BMI, 43.9 kg/m2) who was on stable replacement therapy
for Hashimoto’s thyroiditis. In January 2011, she underwent
Roux-en-Y gastric bypass surgery. She was euthyroid receiv-
ing 150 μg of L-T4 daily in tablet form. One year after
surgery, she had lost 34 kg. At that time, her serum TSH
was 17.2mIU/L, fT4was 11.0 pg/mL, and fT3was 2.8 pg/mL.
We replaced her L-T4 tablets with an oral liquid formulation,
maintaining the same dosage. Euthyroidism was restored after
2 months. Once again, re-administration of L-T4 at the same
dosage in tablet form resulted in an increase in serum TSH
(Table 1).
Discussion
All four of the hypothyroid patients described in this report
had a substantial decrease in serum TSH levels after
switching from treatment with thyroxine tablets to an oral
liquid formulation.
After oral administration, approximately 60–90 % of an L-
T4 dose is absorbed within 3 h of ingestion. A majority of the
absorption takes place in the jejunum and ileum [11]. Absorp-
tion is maximal when administered on an empty stomach,
reflecting the importance of gastric acidity in the process.
For this reason, L-T4 is usually taken with water in the
morning before breakfast [12]. Benvenga et al., clearly
showed that ingesting L-T4 treatment with coffee, or with
water followed by coffee within a few minutes, results in poor
TSH response in many patients [13]. Moreover, concomitant
assumption of a number of drugs and other substances can
reduce L-T4 absorption; these include aluminium hydroxide
[14], sucrafate [15], ferrous sulphate [16], cholestyramine
[17], calcium carbonate [18] and fibre supplements [19].
Drug malabsorption is a potential concern after bariatric
surgery, particularly after diversionary procedures. All of our
Table 1 Thyroid parameters measured at the indicated times in four patients who underwent bariatric surgery between 2009 and 2011. Patients were
receiving oral L-T4 in either tablet or liquid form as indicated
Before surgery L-T4 in tablet
form
12 Months after surgery L-T4 in
tablet form
14 Months after surgeryL-T4 in
liquid form
17 Months after surgery L-T4 in
tablet form
Patient L-T4 (μg) TSH fT4 fT3 L-T4 (μg) TSH fT4 fT3 L-T4 (μg) TSH fT4 fT3 L-T4 (μg) TSH fT4 fT3
1 200 4.2 12.7 3.1 200 18.1 10.4 2.9 200 1.5 12.9 3.8 200 36.7 9.8 3.0
2 150 3.1 12.9 3.3 150 12.1 10.2 3.2 150 1.9 13.5 4.0 150 24.7 10.4 3.2
3 200 3.9 11.7 3.7 200 20.4 10.2 3.3 200 0.6 13.5 3.2 200 17.7 10.2 3.1
4 150 3.6 10.9 3.2 150 17.2 11.0 2.8 150 2.4 11.9 3.2 150 15.3 10.1 3.1
L-T4 levothyroxine, TSH thyrotropin, fT4 free tyroxine, fT3 free triiodothyronin
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patients underwent Roux-en-Y gastric bypass (RYGB), which
bypasses almost the entire stomach. It consisted of transecting
the upper stomach, creating a small proximal gastric pouch,
which is then anastomosed to the proximal jejunum. A recent
review by Padwall et al. points out that highly lipophilic drugs
and/or those that undergo enterohepatic recirculation, such as
levothyroxine, have the greatest potential for malabsorption
after bariatric surgery [3].
Our observations are at odds with the findings of Rubio
et al., who compared the mean absorption of L-T4 tablets in
15 obese patient candidates for RYGB bypass surgery, with
that of 15 patients who had undergone such surgery 2–3-
months previously and found no significant difference be-
tween groups regarding L-T4 absorbance [6]. There are some
differences between our observations and this study. Patients
in this study had undergone surgery 2–3 months prior to
assessment, while in all four of our patients, the aberrant
thyroid parameters were apparent 12 months after surgery. In
addition, three of our four patients were receiving L-T4 for
hypothyroidism due to Hashimoto’s thyroiditis, while all 15
patients who underwent surgery in the study by Rubio et al.
had thyroid nodular disease. Indeed, the authors pointed
to altered L-T4 absorption in some patients as a reason
to monitor thyroid function parameters carefully after
RYGB in patients on stable L-T4 treatment [6]. In
agreement with Azizi et al. and Bevan et al. [9, 10],
the serum TSH levels in our patients increased after
bypass surgery, suggesting a malabsorption of L-T4.
Interestingly, TSH levels normalised after switching
from tablets to liquid oral formulation, and both fT4
and fT3 increased into the normal range. Consistent with
a hypothesis of reduced absorption of tablets, TSH levels
returned to high-normal 2 months after re-introduction of tablets.
To our knowledge, this is the first report showing revers-
ible normalisation of serum TSH levels in patients submitted
to bariatric surgery who received L-T4 in tablet form after
switching to an oral liquid formulation. At present, we do not
have an explanation for this observation. The fact that the
change from tablets to oral formulation normalised serum
TSH levels, and that switching back to tablets caused thyro-
tropin levels to worsen, leads us believe that absorption of
thyroxine is greater with oral liquid formulations in our
patients after bariatric surgery.
Patients with impaired acid secretion require a higher dose
of thyroxine, suggesting that normal gastric acid secretion is
necessary for effective absorption of L-T4 [7]. Drug dissolu-
tion and solubility may be altered by restrictive procedures
that increase gastric pH in the newly created stomach pouch.
This may occur in gastric bypass or gastroplasty, in which
the new gastric pouch is partitioned from acid-producing
cells in the remaining stomach [3]. Recently, Saraceno
et al. have shown that the liquid formulation of L-T4 is an
extremely effective means to circumvent the problem of
incomplete absorption of the L-T4 of caused by proton pump
inhibitor-induced increases in gastric pH [20]. It is conceiv-
able that this formulation could also circumvent the pH
alteration resulting from gastric bypass.
Another hypothesis is that the presence of alcohol (only in
the liquid formulation) could play a key role in thyroxine
absorption. Indeed, oral mucosal drug delivery is known as
an alternative method for systemic drug delivery that offers
several advantages over both injectable and enteral methods
[21]. Because the oral mucosa is highly vascularised, drugs
that are absorbed through the oral mucosa directly enter the
systemic circulation, bypassing the gastrointestinal tract
[21]. Consistent with this hypothesis, we would expect to
see more rapid pharmacokinetics if oral liquid thyroxine can
be absorbed by oral mucosa. Further studies are needed to
clarify this intriguing point.
Finally, it is important to underline that liquid T4 formu-
lation (Tirosint® fiala monouso, IBSA Farmaceutici Italia) is
today available only in Italy, and that at the dosage of 100 μg
daily is more expensive that tablets (0.06 than 0.33 Euro,
respectively, daily).
In summary, we report four patients submitted to
bariatric surgery, in whom oral liquid L-thyroxine in-
duced a reversible normalisation of thyrotropin levels.
It is likely that patients affected by condition that
impair L-T4 absorption (e.g., bariatric surgery) could
benefit from a liquid formulation.
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